Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer

Science
Naiyer A RizviTimothy A Chan

Abstract

Immune checkpoint inhibitors, which unleash a patient's own T cells to kill tumors, are revolutionizing cancer treatment. To unravel the genomic determinants of response to this therapy, we used whole-exome sequencing of non-small cell lung cancers treated with pembrolizumab, an antibody targeting programmed cell death-1 (PD-1). In two independent cohorts, higher nonsynonymous mutation burden in tumors was associated with improved objective response, durable clinical benefit, and progression-free survival. Efficacy also correlated with the molecular smoking signature, higher neoantigen burden, and DNA repair pathway mutations; each factor was also associated with mutation burden. In one responder, neoantigen-specific CD8+ T cell responses paralleled tumor regression, suggesting that anti-PD-1 therapy enhances neoantigen-specific T cell reactivity. Our results suggest that the genomic landscape of lung cancers shapes response to anti-PD-1 therapy.

References

Aug 6, 1970·The New England Journal of Medicine·D Doniach
Mar 29, 2001·Proceedings of the National Academy of Sciences of the United States of America·T Matsutake, P K Srivastava
Jul 17, 2001·Chemical Research in Toxicology·D HoffmannK El-Bayoumy
Apr 4, 2003·Genes & Development·Xin WangLei Li
Apr 30, 2003·Protein Science : a Publication of the Protein Society·Morten NielsenOle Lund
Mar 8, 2005·Mutation Research·Gerd P PfeiferAhmad Besaratinia
Feb 8, 2006·Nature Medicine·Mireille ToebesTon N M Schumacher
Apr 5, 2007·Nature Protocols·Boris RodenkoHuib Ovaa
Dec 17, 2008·Proceedings of the National Academy of Sciences of the United States of America·Jianda YuanJedd D Wolchok
May 20, 2009·Bioinformatics·Heng Li, Richard Durbin
Nov 26, 2009·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Jedd D WolchokF Stephen Hodi
Mar 3, 2010·Genome Medicine·Marc ViaEsteban González Burchard
Apr 1, 2010·Nature Methods·Ivan A AdzhubeiShamil R Sunyaev
Jun 8, 2010·The New England Journal of Medicine·F Stephen HodiWalter J Urba
Jan 12, 2011·Nature Biotechnology·James T RobinsonJill P Mesirov
Nov 15, 2011·Nucleic Acids Research·Greet De BaetsFrederic Rousseau
Jan 13, 2012·Cancer Research·John C CastleUgur Sahin
Feb 10, 2012·Nature·Hirokazu MatsushitaRobert D Schreiber
Apr 14, 2012·Nature Protocols·Rikke Sick AndersenSine Reker Hadrup
May 15, 2012·Bioinformatics·Christopher T SaundersR Keira Cheetham
Jun 5, 2012·The New England Journal of Medicine·Suzanne L TopalianMario Sznol
Sep 11, 2012·Nature·UNKNOWN Cancer Genome Atlas Research Network
Sep 18, 2012·Cell·Ramaswamy GovindanRichard K Wilson
Sep 28, 2012·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Snjezana DoganMarc Ladanyi
Feb 12, 2013·Nature Biotechnology·Kristian CibulskisGad Getz
Mar 30, 2013·Science·Bert VogelsteinKenneth W Kinzler
Jun 4, 2013·The New England Journal of Medicine·Jedd D WolchokMario Sznol
Jun 12, 2013·Nucleic Acids Research·Chang LiuJohn D Pfeifer
Aug 16, 2013·Nature·Ludmil B AlexandrovMichael R Stratton
Sep 18, 2013·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Nienke van RooijTon N Schumacher
Apr 10, 2014·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Janis M TaubeRobert A Anders

❮ Previous
Next ❯

Citations

Jan 19, 2016·Future Oncology·Inês-de-Paula MonteiroRamon Andrade de Mello
Dec 17, 2015·Nature Reviews. Clinical Oncology·Peter SavasSherene Loi
Feb 14, 2016·Immunity·Christina PfirschkeMikael J Pittet
Jan 23, 2016·Expert Opinion on Biological Therapy·Sung Hee LimMyung-Ju Ahn
Feb 5, 2016·Journal of Genetics and Genomics = Yi Chuan Xue Bao·Jingwu Xie, Xiaoli Zhang
Feb 18, 2016·Journal of Hematology & Oncology·Zhenbo TuQiuping Zhang
Nov 18, 2015·Immunological Investigations·Thinle ChodonKunle Odunsi
Nov 22, 2015·Expert Review of Anticancer Therapy·Thu Oanh DangAlexander Drilon
Nov 17, 2015·Expert Review of Anticancer Therapy·Carlo GenovaFrancesco Grossi
Nov 13, 2015·Expert Review of Molecular Diagnostics·Jan Trøst Jørgensen
Nov 18, 2015·Expert Opinion on Biological Therapy·Nicolas Guibert, Julien Mazières
Jan 18, 2016·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Luisella RighiMauro Papotti
Apr 4, 2015·Science·Padmanee Sharma, James P Allison
Apr 4, 2015·Science·Ton N Schumacher, Robert D Schreiber
Jul 25, 2015·Expert Opinion on Biological Therapy·Martina SanlorenzoDario Sangiolo
Jan 23, 2016·Expert Review of Vaccines·Constantin N Baxevanis, Sonia A Perez
Dec 29, 2015·Current Opinion in Immunology·Etienne BechtWolf Herman Fridman
Dec 31, 2015·Current Opinion in Immunology·Mathias VormehrUgur Sahin
Nov 27, 2015·Current Opinion in Immunology·David H Munn, Vincenzo Bronte
Mar 13, 2016·Seminars in Oncology·Paul G Kluetz, Richard Pazdur
Nov 26, 2015·Annals of Oncology : Official Journal of the European Society for Medical Oncology·S W Piraino, S J Furney
Mar 5, 2016·Oncoimmunology·Sylvain SimonN Labarriere
Jul 5, 2016·Bladder Cancer·S BidnurP C Black
Oct 17, 2015·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Antonio CallesPasi A Jänne
Aug 5, 2015·Biochimica Et Biophysica Acta·Eran OphirLana E Kandalaft
Jul 23, 2015·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Kurtis D DaviesDara L Aisner
Nov 7, 2015·Biochimica Et Biophysica Acta·Sander Kelderman, Pia Kvistborg
Feb 7, 2016·BMC Medicine·Jason M RedmanMichael B Atkins
Jan 19, 2016·Annales de pathologie·Julien AdamSylvie Lantuéjoul
Jan 12, 2016·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Takahiro KarasakiJun Nakajima
Jan 30, 2016·Nature Reviews. Cancer·Emily RaynerDavid N Church
Jan 30, 2016·Nature Reviews. Cancer·Nicholas P RestifoAlexandra Snyder
Mar 5, 2016·Oncoimmunology·Lorenzo GalluzziGuido Kroemer
Jan 21, 2016·Nature Reviews. Clinical Oncology·Elizabeth I Buchbinder, F Stephen Hodi
Oct 27, 2015·Journal of Pathology and Translational Medicine·Yoon Young ChoiJae-Ho Cheong
Mar 1, 2016·Cancer Treatment Reviews·Milind JavleAnirban Maitra
Jan 26, 2016·The Journal of Clinical Investigation·Matthias LeisegangThomas Blankenstein
Nov 6, 2015·Cancer·James J HardingGhassan K Abou-Alfa
Feb 24, 2016·International Journal of Clinical Oncology·Junzo HamanishiIkuo Konishi

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cancer Immunotherapy

Cancer immunotherapy is an important field of research that is looking at controlling cancer and tumor growth by activating the individuals own immune system. Recent studies have utilized chimeric antigen receptor t-cell therapy, immune checkpoint inhibitors and neoantigen vaccines. Discover the latest research on cancer immunotherapy here.

Cancer Genomics (Keystone)

Cancer genomics approaches employ high-throughput technologies to identify the complete catalog of somatic alterations that characterize the genome, transcriptome and epigenome of cohorts of tumor samples. Discover the latest research using such technologies in this feed.

Cell Checkpoints & Regulators

Cell cycle checkpoints are a series of complex checkpoint mechanisms that detect DNA abnormalities and ensure that DNA replication and repair are complete before cell division. They are primarily regulated by cyclins, cyclin-dependent kinases, and the anaphase-promoting complex/cyclosome. Here is the latest research.

Cancer Incidence & Mortality

Cancer has emerged as a global concern due to its increase in incidence and mortality. Efforts are underway to evaluate and develop action plans to reduce the global burden of cancer. Currently, lung cancer, breast cancer and prostate cancer are the leading causes of cancer mortality. Here is the latest research on cancer incidence and mortality.

Apoptosis in Cancer

Apoptosis is an important mechanism in cancer. By evading apoptosis, tumors can continue to grow without regulation and metastasize systemically. Many therapies are evaluating the use of pro-apoptotic activation to eliminate cancer growth. Here is the latest research on apoptosis in cancer.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis